Presented by



In collaboration with



Malaysian Oncological Society



Best of ASCO 2020, Malaysia has been awarded 16 CPD points by Academy of Medicine of Malaysia

Scientific Agenda

Scientific Programme

	DAY-1	5 th December 2020	11:55 - 18:55	Malaysian Time
Time	Session Type	Speaker Name	Moderator	Title of Presentation
11:55	Presidential Address	Dr. Muhammad Azrif		Inaugural address
12:00 - 14:00	Pre-Co	nference Workshop - From Be	ench-to-Bedside: The R	ole of Biomarkers in Immunotherapy
12:00 - 12:05	MSD MasterClass	Dr. Azura Rozila Ahmad		Welcome & Opening Remarks
12:05 - 12:40	MSD MasterClass with Q&A	Dr. Pathmanathan Rajadurai	Dr. Azura Rozila Ahmad	Biomarker on the horizon & science behind the biomarker
12:40 - 13:15	MSD MasterClass with Q&A	Dr. Nuttapong Ngamphaiboon	Dr. Azura Rozila Ahmad	Value of PD-L1 testing for H&N cancer IO treatment
13:15 - 13:50	MSD MasterClass with Q&A	Dr. Azura Rozila Ahmad		Value of PD-L1 testing for NSCLC cancer IO treatment
13:50 - 13:55	MSD MasterClass	Dr. Azura Rozila Ahmad		Question & Answer Session
13:55 - 14:00	MSD MasterClass	Dr. Azura Rozila Ahmad		Closing Remarks
14:05 - 14:45		Session 1 - Brea	ast Cancer - Local / Reg	ional / Adjuvant
14:05 - 14:10	Presentation	Dr. Seema Khan		A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
14:10 - 14:15	Presentation	Dr. Jennifer Leong		Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (TDM1) pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high- risk HER2- positive early breast cancer (EBC).
14:15 - 14:20	Presentation	Dr. Cynthia Ma		ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2- negative breast cancer (ER+HER2- BC) in postmenopausal (PM) women: Alliance A011106.
14:20 - 14:25	Presentation	Dr. Ishita Laroiya		MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.
		Dr. Cynthia Ma		
14:30 - 14:45	Panel Discussion & Q&A	Dr. Jennifer Leong	Dr. Aqilah Othman	
		Dr. Ishita Laroiya		

14:50 - 15:30		Session 2 - Brea	ast Cancer - Metastatic
14:50 - 14:55	Presentation	Dr. Javier Cortes	Randomized, double-blind, phase III study of pembrolizumab+ chemotherapy versus placebo + chemotherapy in recurrent inoperable or metastatic triple-negative breast cancer
14:55 - 15:00	Presentation	Dr. Hafizah Zaharah	A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
15:00 - 15:05	Presentation	Dr. Mastura Md Yusof	MONARCH 2: subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer
15:05 - 15:10	Presentation	Dr. Vaishnavi Jeyasingam	PARSIFAL: A randomized, multicenter, open- label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer
		Quick Quiz	1
		Dr. Javier Cortes	
15:15 - 15:30	Panel Discussion & Q&A	Dr. Mastura Md Yusof	Dr. Ang Soo Fan
		Dr. Vaishnavi Jeyasingam	
15:35 - 15:55	Sponsored Session by Zuellig Pharma	Dr. Antonio Lumbart Cussac	CDK4/6 Inhibitor in the Management of Metastatic Breast Cancer: Are they all the same?
15:55 - 16:10		Exhibit	ion Tour Break
16:10 - 16:20		Session 3 - Me	lanoma / Skin Cancers
16:10 - 16:15	Presentation	Dr. Amod Sarnaik	Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
16:15 - 16:20	Presentation	Dr. Shivam Verma	Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.
16:25 - 16:35		Session 4 - Cancer Preven	tion, Risk Reduction and Genetics
16:25 - 16:30	Presentation	Dr. Ho Gwo Fuang	Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counselling during online testing for breast and ovarian cancer genetic risk.
16:30 - 16:35	Presentation	Dr. Aqilah Binti Othman	Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT).

16:40 - 16:45		Session 5	- Sarcoma
16:40 - 16:45	Presentation	Dr. Hadi B. Jalil	Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012).
		Quick Quiz 2	
16:50 - 17:00		Session 6 - Central Ne	rvous System Tumors
16:50 - 16:55	Presentation	Dr. Jennifer Leong	Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C.
16:55 - 17:00	Presentation	Dr. Hafizah Zaharah	Long-Term Analysis of the WHO-Defined Molecular Subgroups of High-Risk Grade II Gliomas Treated with Radiation and Temozolomide on NRG Oncology/RTOG 0424
17:05 - 17:15	Se	ssion 7 - Developmental Therapeutics—Mo	lecularly Targeted Agents and Tumor Biology
17:05 - 17:10	Presentation	Dr. Lim Yueh Ni	Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial
17:10 - 17:15	Presentation	Dr. Chandan Das	Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial
		Quick Quiz 3	
17:15 - 17:30		Exhibition	Tour Break
17:30 - 17:40		Session 8 - Gastrointestinal	Cancer—Colorectal and Anal
17:30 - 17:35	Presentation	Dr. Salvatore Siena	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
17:35 - 17:40	Presentation	Dr. Alberto F. Sobrero	Overall survival (OS) and long-term disease- free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
17:45 - 18:15	:	Session 9 - Gastrointestinal Cancer—Gastro	oesophageal, Pancreatic and Hepatobiliary
17:45 - 17:50	Presentation	Dr. Tan Chih Kiang	Efficacy, Tolerability and Biologic Activity of a Novel Regimen of Tremelimumab (T) in Combination with Durvalumab (D) for Patients (pts) with Advanced Hepatocellular Carcinoma (aHCC).
17:50 - 17:55	Presentation	Dr. Junie Khoo YY	Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study
17:50 - 17:55	Presentation	Dr. Junie Khoo YY Quick Quiz 4	microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer:

18:15 - 18:35		Session 10 - Genitourinary Cancer—Kidney and Bladder		
18:15 - 18:20	Presentation	Dr. Adlinda Alip	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum- based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.	
18:20 - 18:25	Presentation	Dr. Maha H.A. Hussain	IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).	
18:25 - 18:30	Presentation	Dr. Wong Yoke Fui	Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.	
18:30 - 18:35	Presentation	Dr. Michael Atkins	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).	
18:40 - 18:55		Quiz S	Session 1	



		6 th December 2020		
Time	Session Type	Speaker Name	Moderator	Title of Presentation
10:55	Presidential Address	Dr. Muhammad Azrif		Welcome Address
11:00 - 11:40		Session 11 - Genitourina	ary Cancer—Prosta	te, Testicular and Penile
11:00 - 11:05	Presentation	Dr. Teng Aik Ong		Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).
11:05 - 11:10	Presentation	Dr. Aditya P. Sharma		Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistar prostate cancer (nmCRPC).
11:10 - 11:15	Presentation	Dr. Kalpesh Parmar		Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
11:15 - 11:20	Presentation	Dr. Cheah Soon Keat		Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).
		Quick	Quiz 1	
		Dr. Cheah Soon Keat		
11:25 - 11:40	Panel Discussion & —	Dr. Teng Aik Ong	Dr. Junie	
	Q&A	Dr. Kalpesh Parmar	Khoo YY	
		Dr. Aditya P. Sharma		
11:45 - 12:20		Session 12 - Lung	Cancer - Non-Sm	all Cell Metastatic
	Drocentation	Dr. Navneet Singh		Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously
11:45 - 11:50	Presentation			untreated metastatic nonsquamous non- small cell lung cancer (NSCLC)
11:45 - 11:50 11:50 - 11:55	Presentation	Dr. Tan Chih Kiang		
		Dr. Tan Chih Kiang		small cell lung cancer (NSCLC) Trastuzumab deruxtecan (T-DXd; DS-8201 in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interir

12:05 - 12:20	Panel Discussion &	Dr. Tan Chih Kiang	Dr. Liam Chong Kin	
	Q&A	Dr. Navneet Singh	5	
12:25 - 13:00		Session 13	- Gynecologic C	Cancer
12:25 - 12:30	Presentation	Dr. Hafizah Zaharah Binti Ahmad		Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
12:30 - 12:35	Presentation	Dr. Rozita Abdu Malik		A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum- sensitive ovarian cancer.
12:35 - 12:40	Presentation	Dr. Bhavana Rai		Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20
12:40 - 12:45	Presentation	Dr. Aashima Arora		Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer.
		Quick Qui	z 3	
	Panel	Dr. Aashima Arora		
12:50 - 13:05	Discussion & Q&A	Dr. Bhavana Rai	Dr. S. C. Saha	
12:50 - 13:05 13:10 - 13:40	Discussion &		Dr. S. C. Saha Head and Neck	Cancer
	Discussion &		,	Cancer KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
13:10 - 13:40	Discussion & Q&A	Session 14 -	,	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/ metastatic (R/M) head and neck squamous
13:10 - 13:40 13:10 - 13:15	Discussion & Q&A Presentation	Session 14 -	,	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of
13:10 - 13:40 13:10 - 13:15 13:15 - 13:20	Discussion & Q&A Presentation Presentation	Session 14 -	,	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). Randomized phase II study of axitinib versus observation in patients with recurred
13:10 - 13:40 13:10 - 13:15 13:15 - 13:20 13:20 - 13:25	Discussion & Q&A Presentation Presentation Presentation	Session 14 - Session 14 - Wan Zamaniah Wan Ishak Dr. Naomi Kiyota Dr. Bhumsuk Keam	Head and Neck	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-
13:10 - 13:40 13:10 - 13:15 13:15 - 13:20 13:20 - 13:25	Discussion & Q&A Presentation Presentation Presentation	Session 14 - Wan Zamaniah Wan Ishak Dr. Naomi Kiyota Dr. Bhumsuk Keam Dr. Robert Ferris	Head and Neck	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-
13:10 - 13:40 13:10 - 13:15 13:15 - 13:20 13:20 - 13:25 13:25 - 13:30	Discussion & Q&A Presentation Presentation Presentation Presentation	Session 14 - Session 14 - <td>Head and Neck</td> <td>KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer. A trial of the ECOG- ACRIN Cancer Research Group (E3311)</td>	Head and Neck	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer. A trial of the ECOG- ACRIN Cancer Research Group (E3311)

14:00 - 14:35		Session 15 - Hematologic Malignanc	ies - Leukemia, MDS and Allotransplant
14:00 - 14:05	Presentation	Dr. Hany Haqimi Wan Hanafi	Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
14:05 - 14:10	Presentation	Dr. Hany Haqimi Wan Hanafi	Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).
14:10 - 14:15	Presentation	Dr. Hany Haqimi Wan Hanafi	Interim analysis (IA) of OPTIC: A dose- ranging study of three ponatinib (PON) starting doses.
14:15 - 14:20	Presentation	Dr. Hany Haqimi Wan Hanafi	Updated Results from Phase I Dose- Escalation Study of AMG 330, a Bispecific T-Cell Engager Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
14:25 - 14:35	Panel Discussion & Q&A		ır. Azlan Iusin
14:40 - 15:10		Session 16 - Hematologic Ma	lignancies - Lymphoma and CLL
14:40 - 14:45	Presentation	Dr. John G. Kuruvilla	Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
14:45 - 14:50	Presentation	Dr. Ganesh Kasinathan	ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).
14:50 - 14:55	Presentation	Dr. Ganesh Kasinathan	Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
14:55 - 15:00	Presentation	Dr. Ganesh Kasinathan	A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter's syndrome.
15:05 - 15:10	Panel Discussion & Q&A		r. Lau Ngee iang
15:15 - 15:55		Session 17 - Hematologic Mal	ignancies-Plasma Cell Dyscrasia
15:15 - 15:20	Presentation	Dr. Shaji Kumar	Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.
15:20 - 15:25	Presentation	Dr. Nur Adila Bt Anuar	Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

15:25 - 15:30	Presentation	Dr. Nur Adila Bt Anuar		Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.
15:30 - 15:35	Presentation	Dr. Nur Adila Bt Anuar		Phase I Study of Teclistamab, a Humanized B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma (R/R MM)
15:40 - 15:55	Panel Discussion & Q&A	Dr. Nur Adila Bt Anuar	Dr. Haris Abdul Rahman	
15:55 - 16:10			Exhibition Tour Break	
16:10 - 17:10		Session 18 - Lung Cancer	- Non-Small Cell Local	-Regional/Small Cell/Other
16:10 - 16:15	Presentation	Dr. Roy S. Herbst		Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
16:15 - 16:20	Presentation	Dr. Tang Weng Heng		Durvalumab ± tremelimumab + platinum- etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study.
16:20 - 16:25	Presentation	Dr. Hye Ryun Kim		Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
16:25 - 16:30	Presentation	Dr. Yi-Long Wu		Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.
16:30 - 16:45	Panel Discussion & Q&A	Dr. Roy S. Herbst	Dr. Jennifer Leong	
16:50 - 17:05			Quiz Session 2	
17:10 Onwards		Valed	ictory & Awards' Decla	ration

BESTOFASCO ASCO20 Virtual

LEADERBOARD & AWARDS SPONSORED BY ASCO



Winners will be declared in the end of the Conference (Approx. 17:00 – 17:30) on Day 2, 6th December, 2020.



ASK YOUR BEST QUESTIONS AND WIN EXICITING AWARDS



SPONSORED BY

MR./MS. CROSS EXAMINER

Mr./Ms. Cross Examiner will be awarded to delegates who will drop most relevant questions in the Q&A box during each session.

ASK RELEVENT QUESTIONS DURING THE CONFERENCE AND STAND A CHANCE TO WIN AWARDS SPONSORED BY ASCO



1st Position Digital Access to ASCO20 Videos and Slides





2nd Position Digital Access to IO Symposium Videos and Slides



3rd Position Digital Access to 2020 Educational Book

Winners will be declared in the end of the Conference (Approx. 17:00 – 17:30) on Day 2, 6th December, 2020.



Best of ASCO ASCO2020® Virtual Conference a program licensed by the American Society of Clinical Oncology, Inc.

Thank you Partners

Patron Partner



Diamond Partner



Lilly


Gold Partner Gold Partner Boehringer Ingelheim

Exhibitor





MAKING MORE TOMORROWS POSSIBLE FOR PATIENTS





Scan the QR code to access the Selected Safety Information

References: 1. Garon EB, et al. 5-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. *J Clin Oncol* 37. Presented at ASCO 2019. **2.** Brahmer JR, et al. KEYNOTE-024 5-year OS update: first-line pembrolizumab vs platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer and PD-L1 tumor proportion score \geq 50%. Presented at Virtual ESMO 2020.

For Healthcare Professionals Only

Before prescribing KEYTRUDA $^{\! \otimes}$, please read the Local Product Circular.

Copyright© 2020 Merck Sharp & Dohme (M) Sdn. Bhd., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. MY-KEY-00431 Nov/2020

(pembrolizumab) Injection 100 mg

Lilly



Today impacts tomorrow's choices

How do you maximize survival for your EGFR M+ NSCLC patients?





Time for life







In collaboration with Malaysian Oncological Society

5th & 6th December 2020 *Malaysia*



Building Community

Support Desk 90306 95668 | 81306 06116 | 88006 91399 | 86555 64901

